Huntington's disease (HD) is an inherited, progressive neurological disorder that is caused by a CAG/polyglutamine repeat expansion and for which there is no effective therapy. Recent evidence indicates that transcriptional dysregulation may contribute to the molecular pathogenesis of this disease.
Histone deacetylase inhibitors (HDAC inhibitors or HDI) are an emerging class of anticancer agents with demonstrable preclinical antitumor activity in both in vitro and in vivo studies in a wide range of malignancies.
Based on these preclinical findings, in recent years HDACIs have undergone a rapid phase of clinical development with many HDACIs entering Phase I–III clinical trials, both as single agents and in combination with other therapies.
In fact, several compounds in this class, including Suberoylanilide hydroxamic acid (SAHA), MS-27-275, BML-210, M344 and CI-994, are currently undergoing clinical trials.
At the moment we can offer you the following HDAC inhibitors from stock: Suberoylanilide Hydroxamic Acid (SAHA); MS-275 (Entinostat); CI-994 (Tacedinaline); BML-210; M344; MGCD0103 (Mocetinostat); PXD101; LBH-589; Tubastatin A. All these compounds are in stock and can be delivered in 5-10 days. The minimum purity of HDAC inhibitors is 98%. H1NMR and LCMS analytical data are available upon request.
The following HDAC inhibitors can be delivered in about 3-6 weeks: Scriptaid; NSC 3852; NCH 51; HNHA; BML-281; CBHA; Salermide; Pimelic Diphenylamide; ITF2357 (Givinostat); PCI-24781; APHA Compound 8; Droxinostat; SB939.
Special offer
We are pleased to offer you set of eight HDAC inhibitors* at the best current market price:
$600/8 inhibitors* x 10 mg
$1100/8 inhibitors* x 50 mg
$1450/8 inhibitors* x 100 mg
Shipping and handling costs: $150
Delivery time: 5-10 days by courier from stock.
This special sale is for limited time only
* - Suberoylanilide Hydroxamic Acid (SAHA);
Entinostat (MS-275);
Tacedinaline (CI-994);
BML-210;
M344;
Mocetinostat (MGCD0103);
PXD101;
LBH-589.
All fields are required.